The progress achieved in treating huge swathes of the world’s HIV-infected population in the last 20 to 30 years might give the impression of a therapy area where few challenges remain.
At the same time, the success of Gilead Sciences (Nasdaq: GILD) in becoming the leader in market share and gaining approval for Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), a once-daily single-tablet regimen that is predicted to have peak annual sales of up to $10 billion, might suggest that other companies are just looking to fill in the gaps in the coverage provided by the US biotech giant’s treatments.
Both assumptions would be entirely wrong, according to Deborah Waterhouse (pictured above), chief executive of Viiv Healthcare, the independent HIV specialist company majority-owned by the UK's GlaxoSmithKline (LSE: GSK) and partnered with Pfizer (NYSE: PFE) and Shionogi (TYO: 4507).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze